; and (iii) have an agreement with multiple eligible health care sites described in subparagraph (B). (3) Preference In awarding grants under this section, the Secretary may give preference to eligible entities described in paragraph (2) that meet either or both of the following criteria: (A) The eligible health care site is, or the eligible health care site coordinator has an agreement described in paragraph (2)(C)(iii) with a site that is, a critical access hospital (as defined in section 1861(mm)(1) of the Social Security Act ( 42 U.S.C. 1395x(mm)(1) )), a low-volume hospital (as defined in section 1886(d)(12)(C)(i) of such Act ( 42 U.S.C. 1395ww(d)(12)(C)(i) )), or a sole community hospital (as defined in section 1886(d)(5)(D)(iii) of such Act ( 42 U.S.C. 1395ww(d)(5)(D)(iii) )). (B) The eligible health care site or the eligible health care site coordinator is located in a geographic area with a drug overdose rate that is higher than the national rate, or in a geographic area with a rate of emergency department visits for overdoses that is higher than the national rate, as determined by the Secretary based on the most recent data from the Centers for Disease Control and Prevention. (4) Medication-assisted treatment defined For purposes of this section, the term medication-assisted treatment means the use of a drug approved under section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) or a biological product licensed under section 351 of the Public Health Service Act ( 42 U.S.C. 262 ), in combination with behavioral health services, to provide an individualized approach to the treatment of substance use disorders, including opioid use disorders. (c) Period of grant A grant awarded to an eligible entity under this section shall be for a period of at least 2 years. (d) Grant uses (1) Required uses A grant awarded under this section to an eligible entity shall be used for both of the following purposes: (A) To establish policies and procedures that address the provision of overdose reversal